Theriva Biologics Net Worth
Theriva Biologics Net Worth Breakdown | TOVX |
Theriva Biologics Net Worth Analysis
Theriva Biologics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Theriva Biologics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Theriva Biologics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Theriva Biologics' net worth analysis. One common approach is to calculate Theriva Biologics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Theriva Biologics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Theriva Biologics' net worth. This approach calculates the present value of Theriva Biologics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Theriva Biologics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Theriva Biologics' net worth. This involves comparing Theriva Biologics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Theriva Biologics' net worth relative to its peers.
Enterprise Value |
|
To determine if Theriva Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theriva Biologics' net worth research are outlined below:
| Theriva Biologics generated a negative expected return over the last 90 days | |
| Theriva Biologics has high historical volatility and very poor performance | |
| Theriva Biologics may become a speculative penny stock | |
| Theriva Biologics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Theriva Biologics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from medcitynews.com: Health Leaders Applaud Bidens Proposal to Expand MedicareMedicaid Coverage for Anti-Obesity Medications |
Theriva Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theriva Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theriva Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow Theriva Biologics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.73 M.Market Cap |
|
Project Theriva Biologics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.46) | (0.49) |
When accessing Theriva Biologics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Theriva Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theriva Biologics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Theriva Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theriva Biologics. Check Theriva Biologics' Beneish M Score to see the likelihood of Theriva Biologics' management manipulating its earnings.
Evaluate Theriva Biologics' management efficiency
Theriva Biologics has return on total asset (ROA) of (0.2498) % which means that it has lost $0.2498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5906) %, meaning that it created substantial loss on money invested by shareholders. Theriva Biologics' management efficiency ratios could be used to measure how well Theriva Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.65 in 2024. Return On Capital Employed is likely to rise to -0.42 in 2024. At this time, Theriva Biologics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.2 M in 2024, whereas Total Current Assets are likely to drop slightly above 14.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 61.64 | 109.45 | |
| Tangible Book Value Per Share | 22.11 | 21.01 | |
| Enterprise Value Over EBITDA | 0.71 | 0.75 | |
| Price Book Value Ratio | 0.17 | 0.17 | |
| Enterprise Value Multiple | 0.71 | 0.75 | |
| Price Fair Value | 0.17 | 0.17 | |
| Enterprise Value | -29.8 M | -28.3 M |
The leadership approach at Theriva Biologics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Return On Equity (0.59) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theriva Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theriva Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theriva Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kraws Jeffrey J over six months ago Acquisition by Kraws Jeffrey J of 110000 shares of Theriva Biologics subject to Rule 16b-3 |
Theriva Biologics Earnings per Share Projection vs Actual
Theriva Biologics Corporate Management
| Steven CPA | CFO, CEO | Profile | |
| Vincent Perrone | Director Communication | Profile | |
| Frank Tufaro | Chief Officer | Profile | |
| Vince Wacher | Head Development | Profile | |
| Lara Guzman | Director Operations | Profile | |
| Ramon Alemany | Senior Board | Profile | |
| Michael MD | Senior Development | Profile |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.